VERA vs. LNTH, ELAN, RVMD, VKTX, ASND, CYTK, KRYS, NUVL, BPMC, and OGN
Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Lantheus (LNTH), Elanco Animal Health (ELAN), Revolution Medicines (RVMD), Viking Therapeutics (VKTX), Ascendis Pharma A/S (ASND), Cytokinetics (CYTK), Krystal Biotech (KRYS), Nuvalent (NUVL), Blueprint Medicines (BPMC), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical products" industry.
Vera Therapeutics (NASDAQ:VERA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
Vera Therapeutics currently has a consensus target price of $51.75, indicating a potential upside of 37.96%. Lantheus has a consensus target price of $126.00, indicating a potential upside of 19.37%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Lantheus.
Lantheus has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantheus had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 12 mentions for Lantheus and 10 mentions for Vera Therapeutics. Lantheus' average media sentiment score of 1.51 beat Vera Therapeutics' score of 0.83 indicating that Lantheus is being referred to more favorably in the news media.
99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 21.7% of Vera Therapeutics shares are owned by insiders. Comparatively, 1.5% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Lantheus received 307 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.69% of users gave Lantheus an outperform vote while only 58.33% of users gave Vera Therapeutics an outperform vote.
Vera Therapeutics has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500.
Lantheus has a net margin of 29.80% compared to Vera Therapeutics' net margin of 0.00%. Lantheus' return on equity of 48.36% beat Vera Therapeutics' return on equity.
Summary
Lantheus beats Vera Therapeutics on 12 of the 18 factors compared between the two stocks.
Get Vera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vera Therapeutics Competitors List
Related Companies and Tools
Free VERA Stock Alerts